These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 803104)

  • 1. Expansion of the growth fraction in multiple myeloma with alkylating agents.
    Salmon SE
    Blood; 1975 Jan; 45(1):119-29. PubMed ID: 803104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The growth fraction of human myeloma cells.
    Drewinko B; Alexanian R; Boyer H; Barlogie B; Rubinow SI
    Blood; 1981 Feb; 57(2):333-8. PubMed ID: 7448427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.
    Alberts DS; Durie BG; Salmon SE
    Cancer Treat Rep; 1977; 61(3):381-8. PubMed ID: 872138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth patterns in multiple myeloma.
    Hokanson JA; Brown BW; Thompson JR; Drewinko B; Alexanian R
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    Cavo M; Galieni P; Tassi C; Gobbi M; Tura S
    Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic index for multiple myeloma.
    Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
    Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
    Hofmann V; Salmon SE; Durie BG
    Blood; 1981 Sep; 58(3):471-6. PubMed ID: 7259835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
    Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
    Cantore M; Smerieri F; Bucalossi A; Leoncini L
    Recenti Prog Med; 1991 Nov; 82(11):598-602. PubMed ID: 1763233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
    Jagannath S; Barlogie B; Dicke K; Alexanian R; Zagars G; Cheson B; Lemaistre FC; Smallwood L; Pruitt K; Dixon DO
    Blood; 1990 Nov; 76(9):1860-6. PubMed ID: 2224133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
    Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
    Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.